Xiaofan Jiang
Shenyang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Correction: Targeting SOST using a small‑molecule compound retards breast cancer bone metastasis.
Journal: Molecular cancer
Published: April 16, 2025
Erratum to: FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.
Journal: Science China. Life sciences
Published: March 18, 2025
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.
Journal: Nature communications
Published: February 19, 2025
Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies.
Journal: Signal transduction and targeted therapy
Published: June 23, 2024
Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study.
Journal: eLife
Published: August 08, 2023
FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.
Journal: Science China. Life sciences
Published: February 08, 2023
Targeting SOST using a small-molecule compound retards breast cancer bone metastasis.
Journal: Molecular cancer
Published: October 27, 2022
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
Journal: Nature communications
Published: July 27, 2022
Characteristics and survival in bone metastatic breast cancer patients with different hormone receptor status: A population-based cohort study.
Journal: Frontiers in oncology
Published: June 24, 2022
Modulation of Immune Components on Stem Cell and Dormancy in Cancer.
Journal: Cells
Published: August 29, 2021
Showing 1-12 of 12
Last Updated: 09/26/2026